Comparative Pharmacology
Head-to-head clinical analysis: BUTRANS versus DOLISHALE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTRANS versus DOLISHALE.
BUTRANS vs DOLISHALE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
None Documented
None Documented
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic